Medical data and technology company HeraMED Limited (ASX:HMD) has commenced a paid pilot of its HeraCARE solution involving 100 expectant mothers.
CEO and Cofounder, David Groberman, said this milestone represents the initial phase of an anticipated commercial roll-out for the use of HeraMED’s technology as a standard service to be offered to all pregnant mothers under JHC’s care.
Since this pilot was first announced in April 2021, HeraMED’s team including a dedicated local project manager has been working closely with JHC’s obstetrics department and the midwives that are leading the pilot, to ensure the HeraCARE platform is fully integrated with the workflows and clinical pathways.
All parties have been focused on configuring and optimising the platform to accommodate JHC’s requirements, as well as providing training to the project’s staff.
The paid pilot represents the last stage of the collaboration in which JHC is undertaking to incorporate the HeraCARE platform to introduce an innovative model for remote monitoring and care management for pregnant women, allowing for the HeraBEAT device and foetal heart rate data to be used in telehealth consultations.
Last year, HeraMED announced outstanding results from a clinical study undertaken by JHC that delivered clinical and functional validation of the HeraBEAT device. The accuracy of the HeraBEAT device was found to be excellent when compared to the industry standard CTG (Phillips Avalon) machine. The Foetal Heart Rate (FHR) was detected on 100% of occasions by clinicians and importantly, the FHR was detected on 100% of occasions by the expectant mothers when using the device without assistance.
This represents the second paid pilot that HeraMED has commenced this month, following the announcement on 19 July, regarding the paid pilot commencing at Obstetrix Medical Group in United States.
As part of Australia’s largest private hospital operator; Ramsay Health Care Group, JHC are well regarded as early adopters of new technologies in obstetrics and I am delighted that their paid pilot has commenced, representing an important next step in our collaboration,” Mr Groberman said.
JHC CEO, Dr Amanda Ling, said that if this pilot is successful, the Campus would hope to incorporate the platform into its remote monitoring and care management programmes for pregnant women.
“At JHC, we are continually evaluating and adopting new technology that will improve the patient care and this agreement is a demonstration of that strategy at work,” she said.
